Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from Saniona AB ( (SE:SANION) ) is now available.
Saniona will present its programs and strategy at a series of investor and partnering conferences across Europe and the U.S. during the spring and summer, including events in Stockholm, New York, Copenhagen and San Diego. The company’s active conference schedule underscores its efforts to raise visibility among investors and potential partners, support business development around its neurology and psychiatry pipeline and strengthen its positioning within the biopharmaceutical sector.
The most recent analyst rating on (SE:SANION) stock is a Buy with a SEK16.50 price target. To see the full list of analyst forecasts on Saniona AB stock, see the SE:SANION Stock Forecast page.
More about Saniona AB
Saniona AB is a clinical-stage biopharmaceutical company focused on discovering, developing and delivering innovative treatments for neurological and psychiatric disorders. Its internal pipeline includes SAN2668 for paediatric epilepsy syndromes, SAN2219 for epilepsy and SAN2465 for major depressive disorder, complemented by partnered programs in epilepsy, essential tremor and obesity, and it is listed on the Nasdaq Stockholm Main Market.
Average Trading Volume: 999,481
Technical Sentiment Signal: Buy
Current Market Cap: SEK2.15B
See more insights into SANION stock on TipRanks’ Stock Analysis page.